Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.
Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.
Pharma Mar, S.A. (OTCMKTS:PHMMF – Get Free Report)’s share price hit a new 52-week low during trading on Monday . The company traded as low as $32.10 and last traded at $32.10, with a volume of 4 shares traded. The stock had previously closed at $32.10. Pharma Mar Price Performance The stock has a 50 […]
BME Launches IBEX速 ESG Index Family To Promote Sustainability mondovisione.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondovisione.com Daily Mail and Mail on Sunday newspapers.
Pharma Mar (OTCMKTS:PHMMF) Hits New 1-Year Low at $33 34 kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.